Hengrui makes headway with novel drugs but investors bide their time
A cancer drug developed by the Chinese firm has entered the European regulatory process and Novo Nordisk has bought rights to a potential weight-loss therapy Key Takeaways: Hengrui Pharma’s cancer…
Cancer drug sales power up Kelun-Biotech’s profit engine
The firm made more money from precision oncology treatments than from licensing deals in the first half, after gaining insurance coverage for its core drugs in China Key Takeaways: The…
Then there were two: BeOne moves beyond single-blockbuster dependence
The company’s Sonrotoclax is the first newly approved BCL-2 inhibitor in the U.S. in nearly a decade, giving BeOne a potential new hit beyond its Zanubrutinib blood cancer therapy Key…
Drug spin-off trend gains traction with IPO by Hengrui offshoot
A company set up to develop Hengrui Pharma’s weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the “NewCo” business model Key Takeaways: Hengrui’s…
CSPC Pharma teases big bucks deals after earnings miss
The Chinese drug giant revealed it was in talks with three parties to license its products for up to $5 billion in potential fees, a day after it delivered lackluster…
Will Trump’s drug order put the brakes on China’s overseas pharma drive?
The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries Key Takeaways: Pharma…
BeiGene celebrates profit milestone on soaring drug sales
Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis Key Takeaways: Global sales of the company’s…
Recent Articles
Hengrui makes headway with novel drugs but investors bide their time
1276.HK
600276.SHG
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK
688235.SHG
ONC.US
Drug spin-off trend gains traction with IPO by Hengrui offshoot
1276.HK
600276.SHG
BeiGene celebrates profit milestone on soaring drug sales
6160.HK
ONC.US
688325.SHG
RELATED ARTICLES
-
Drug spin-off trend gains traction with IPO by Hengrui offshoot
1276.HK600276.SHG
- Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Can a novel sleeping pill help Jingxin shed its generic label?
002020.SHE
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
-
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK688235.SHGONC.US
